skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Review

(2404) Views  (610) Full article downloads

Authors: Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published Date November 2010 Volume 2010:6 Pages 1023 - 1037
DOI: http://dx.doi.org/10.2147/VHRM.S13496

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Benefits of statin therapy and compliance in high risk cardiovascular patients
Low high-density lipoprotein cholesterol: current status and future strategies for management
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
Optimal management of familial hypercholesterolemia: treatment and management strategies
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University